GO
Loading...

Dendreon Corp

More

  • March 10- Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country, the company said, and its stock jumped as much as 36 percent.

  • March 10- German health regulators have granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small U.S. biotechnology company has not yet completed its late-stage trial of the immunotherapy.

  • Agenus brain cancer vaccine shows promise in study Monday, 16 Dec 2013 | 10:29 AM ET

    Dec 16- Agenus Inc said more than 90 percent of patients treated with its experimental brain cancer vaccine were alive six months after undergoing surgery to remove the tumors. Agenus shares soared as much as 32 percent in early trading.

  • Dec 3- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

  • Dec 3- A former hedge-fund analyst who argued that Dendreon Corp's therapeutic vaccine for prostate cancer may hasten the death of patients has reached a settlement with U.S. securities regulators over failure to disclose her financial interests in the company.

  • Nov 12- Biotechnology company Dendreon Corp said it would reduce annual costs by $125 million and cut about 150 jobs in a new round of restructuring, as it struggles to boost sales of its flagship cancer vaccine. Dendreon's net product revenue, reflecting Provenge sales, fell 13 percent to $68 million in the third quarter ended Sept. 30.

  • Nov 12- Biotechnology company Dendreon Corp said it would restructure to cut costs after reporting another quarter of weak sales of its prostate cancer vaccine, Provenge.

  • Lightning Round: Ford, Five Below & More Monday, 23 Sep 2013 | 6:45 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Early movers: NDAQ, FL, P, GES, ARO, GS & more Friday, 23 Aug 2013 | 7:50 AM ET

    Some of the names on the move ahead of the open.

  • After-hours buzz: JCPenney, Priceline & more Thursday, 8 Aug 2013 | 5:13 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • Midday Movers: BBY, THC & More Friday, 11 Jan 2013 | 12:51 PM ET

    Take a look at some of Friday's midday movers:

  • --Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.

  • --Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.

  • Chief Executive Tim Cook apologized Friday to customers frustrated with glaring errors in its new Maps service and, in an unusual move for the consumer giant, directed them to rival services such as Google Inc's Maps instead. **GOOGLE INC, Friday close $754.50, up 0.6 pct premarket.

  • Chief Executive Tim Cook apologized Friday to customers frustrated with glaring errors in its new Maps service and, in an unusual move for the consumer giant, directed them to rival services such as Google Inc's Maps instead. **GOOGLE INC, Friday close $754.50, up 0.6 pct premarket.

  • Chief Executive Tim Cook apologized Friday to customers frustrated with glaring errors in its new Maps service and, in an unusual move for the consumer giant, directed them to rival services such as Google Inc's Maps instead. **MICROSOFT CORP, Friday close $29.76, down 0.20 pct premarket. RBC and Jefferies& Co both reduced their price targets on Microsoft's stock.

  • No Magic in Anti-Obesity Pills and Profits Monday, 16 Jul 2012 | 6:17 PM ET

    Jim Cramer’s researcher, Nicole Urken, reiterates the importance of assessing risk when speculating.

  • Stocks to Watch: GOOG, GRPN, ELY & More Wednesday, 11 Jul 2012 | 1:44 PM ET

    Take a look at some of Wednesday's midday movers:

  • Stocks to Watch: GG, AAPL, GSK & More Wednesday, 11 Jul 2012 | 7:54 AM ET

    Take a look at some of Wednesday’s morning movers:

  • 20 Stocks with the Potential to Pop Monday, 2 Jul 2012 | 4:42 PM ET
    It's the basic question when investing in a stock: is it on the way up or down?To answer this question, the street has developed numerous ways of attempting to predict what will happen, estimating various attributes tied to stock performance in order to determine what the future holds for a company's valuation. After dissecting the data, analysts following a particular stock produce a price target of where they believe the stock is headed. With data from Thomson Reuters, CNBC.com took a look at

    From the entire S&P 500, which stocks are analysts expecting to have the biggest pops? Find out!

Most Popular Video

Thursday, 24 Apr 2014 | 2:30 PM ET

Sell in May? It's an old cliché but the problem is it's sometimes right! But earnings keep rolling in better than expected. CNBC's Patti Domm explains.

Thursday, 24 Apr 2014 | 1:16 PM ET

Discussing whether boards of directors are necessary for companies, and the importance of them pushing back, with Stuart Grant of Grant & Eisenhofer, and Brad Feld, author of "Startup Boards."

Thursday, 24 Apr 2014 | 1:33 PM ET

CNBC's Diana Olick reports DR Horton announced a new bargain brand targeted at the entry-level buyer.